What is it?
Human evidence is the limiting factor
2Reviews describe laboratory and animal findings for Chaga extracts, but these signals do not establish reliable outcomes for supplement users without adequate human studies.
Names, aliases and forms
Mechanisms of action
Preclinical signals are not product proof
3The pharmacology literature describes potential mechanisms from preclinical studies. Those findings provide biological context, not evidence that a Chaga powder, tea or extract improves cognition in people.
Potential effects and evidence map
Chaga has laboratory and animal research, but no adequate clinical studies establishing safety or efficacy. It does not provide reliable human evidence for memory, focus, mood or healthy-user cognitive performance.
No adequate clinical studies demonstrate memory or learning enhancement from Chaga in healthy adults.
No adequate clinical studies demonstrate a focus or attention benefit from Chaga in healthy adults.
Energy and fatigue findings are preclinical and do not establish an everyday human effect.
No adequate clinical studies establish long-term brain-support benefit from Chaga in people.
Safety, side effects and risk profile
Published case reports describe oxalate nephropathy and severe kidney injury after high and/or prolonged Chaga powder ingestion. These reports signal potentially serious harm but do not establish frequency or ordinary labelled-use risk.
Preclinical platelet and glucose findings have uncertain clinical relevance; no human Chaga interaction trial is identified in the supplied sources.
The supplied sources do not establish the frequency of common gastrointestinal effects from Chaga products.
No useful human pregnancy or lactation safety data were identified for Chaga products.
Most efficacy literature is preclinical, and product forms vary widely, so uncertainty is high when comparing consumer products.
The reported kidney events involved oxalate deposition and acute kidney injury after high and/or prolonged powder ingestion. Case reports identify potentially serious events but do not establish a predictable list or frequency of common Chaga side effects.
Interactions and cautions
Chaga extract affected platelet aggregation in a murine model and glucose-related pathways in vitro. The source describes the clinical relevance of potential anticoagulant, antiplatelet or glucose-lowering interactions as unknown.
Legal and regulatory status
As checked on 2026-08-02, FDA does not approve dietary supplements before they are marketed. This is a United States regulatory context; it does not establish Chaga safety, effectiveness or the status of products in other jurisdictions.
How it compares
This profile does not treat Chaga, Reishi and Turkey Tail products as evidence-equivalent. Each mushroom, extract and intended outcome requires its own human evidence and product-identity review.
Practical buying and quality notes
- Offer availability and normalized-price data can change. Compare live listed prices only within the same product form; teabags, raw powder, extracts and capsules are not a single comparable unit.
- Check that the product label identifies Inonotus obliquus. Do not assume another mushroom product shares the same evidence or safety context.1
- For extracts, compare any disclosed extraction method, standardization, serving size and constituent or contaminant testing. Do not treat an extract ratio alone as proof of equivalent composition.
FAQ
Does Chaga have an established dose or cycle?
1No adequate clinical studies establish a research-backed routine dose or cycle to use as a benchmark. Use each product form's own label and ingredients when comparing products; a tea cup, powder scoop, extract and capsule are not dose-equivalent by weight.
References
- Memorial Sloan Kettering Cancer Center. Chaga Mushroom. About Herbs database.
- Phoebe Tee Yon Ern, Tang Yin Quan, Fung Shin Yee, and Adeline Chia Yoke Yin. Therapeutic properties of Inonotus obliquus (Chaga mushroom): A review. Mycology. 2023;15(2):144-161.
- Duru KC, Kovaleva EG, Danilova IG, van der Bijl P. The pharmacological potential and possible molecular mechanisms of action of Inonotus obliquus from preclinical studies. Phytother Res. 2019;33(8):1966-1980.
- Kikuchi Y, Seta K, Ogawa Y, Takayama T, Nagata M, Taguchi T, Yahata K. Chaga mushroom-induced oxalate nephropathy. Clin Nephrol. 2014;81(6):440-444.
- Lee S, Lee HY, Park YJ, et al. Development of End Stage Renal Disease after Long-Term Ingestion of Chaga Mushroom: Case Report and Review of Literature. J Korean Med Sci. 2020.
- Kwon O, Kim Y, Paek JH, Park WY, Han S, Sin H, Jin K. Chaga mushroom-induced oxalate nephropathy that clinically manifested as nephrotic syndrome: A case report. Medicine (Baltimore). 2022;101(10):e28997.
- U.S. FDA. Information for Consumers on Using Dietary Supplements.